DOT1L and breast cancer: ChIP-seq analysis of histone H3 lysine 4 trimethylation (H3K4me3), a marker of active transcription start sites (TSSs), revealed increased numbers of H3K4me3 peaks in breast cancer cells treated with a DOT1L inhibitor (Fig. 4A, Supplementary Fig. S8A).